Statins and diabetes: the good, the bad, and the unknown (Q38072613)

28 August 2017

1 reference

title

Statins and diabetes: the good, the bad, and the unknown (English)

1 reference

28 August 2017

Kelly Axsom

1

1 reference

28 August 2017

Jeffrey S Berger

series ordinal

2

1 reference

28 August 2017

Arthur Z Schwartzbard

series ordinal

3

1 reference

28 August 2017

1 February 2013

1 reference

Current Atherosclerosis Reports

28 August 2017

1 reference

28 August 2017

15

1 reference

28 August 2017

2

1 reference

28 August 2017

299

1 reference

https://scigraph.springernature.com/pub.10.1007/s11883-012-0299-z

28 August 2017

0 references

cites work

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

Executive summary: Standards of medical care in diabetes--2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

Statins for primary prevention of cardiovascular and cerebrovascular events in diabetic patients without established cardiovascular diseases: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

Statins, risk of diabetes, and implications on outcomes in the general population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

HDL and LDL cholesterol significantly influence beta-cell function in type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

Cholesterol metabolism and pancreatic beta-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

Possible contributions of lipoproteins and cholesterol to the pathogenesis of diabetes mellitus type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

Insulin regulation of glucose uptake: a complex interplay of intracellular signalling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients who have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial— Lipid Lowering Arm (ASCOT-LLA)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0299-Z

High-dose atorvastatin after stroke or transient ischemic attack

21 January 2018

1 reference

12 December 2020

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

1 reference

12 December 2020

Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial

1 reference

12 December 2020

Relation between blood glucose and coronary mortality over 33 years in the Whitehall Study

1 reference

12 December 2020

Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial

1 reference

12 December 2020

Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Early statin treatment following acute myocardial infarction and 1-year survival

1 reference

12 December 2020

10.1007/S11883-012-0299-Z

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

0 references

1 reference